Cellular Dynamics International
Date | Investors | Amount | Round |
---|---|---|---|
$18.0m | Series A | ||
$40.6m | Series B | ||
$30.0m | Series B | ||
$21.0m | Growth Equity VC | ||
N/A | $20.0m | Debt | |
N/A | $46.0m Valuation: $204m | IPO | |
$307m Valuation: $307m | Acquisition | ||
Total Funding | €99.6m |
Recent News about Cellular Dynamics International
EditFujifilm Cellular Dynamics, a subsidiary of Fujifilm, specializes in the development and manufacturing of induced pluripotent stem cells (iPSCs) for various applications including drug discovery, safety pharmacology, and regenerative medicine. The company serves pharmaceutical companies, research institutions, and biotech firms by providing high-quality iPSC-derived cells such as cardiomyocytes, neurons, and other specialized cell types. Operating in the biotechnology and life sciences market, Fujifilm Cellular Dynamics leverages its proprietary episomal reprogramming technology to produce iPSCs at an industrial scale. The business model revolves around the sale of iCell products, custom cell development services, and collaborative research agreements. Revenue is generated through product sales, service contracts, and strategic partnerships aimed at advancing therapeutic approaches and drug discovery solutions.
Keywords: iPSCs, drug discovery, regenerative medicine, cardiomyocytes, neurons, biotechnology, life sciences, cell manufacturing, therapeutic approaches, safety pharmacology.